Synlogic announces publication of synpheny-1 phase 2 study of synthetic biotic for phenylketonuria in nature metabolism

Cambridge, mass., sept. 28, 2023 (globe newswire) -- synlogic, inc. (nasdaq: sybx), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the publication of results from its synpheny-1 phase 2 study of its drug candidates, labafenogene marselecobac (synb1934) and synb1618 in patients with phenylketonuria (pku) in the journal nature metabolism.
SYBX Ratings Summary
SYBX Quant Ranking